Amylin Pharmaceuticals, Inc.'s Byetta Will Add Warning About Pancreas Risk

Oct. 16 (Bloomberg) -- Amylin Pharmaceuticals Inc. will warn doctors and patients about the risk of severe inflammation of the pancreas that may occur with the diabetes medicine Byetta, marketed with Eli Lilly & Co.